The U.S. Food and Drug Administration (FDA) recently expanded the use of Sovaldi and Harvoni to adolescents 12 years and older who have hepatitis C virus (HCV). Harvoni was approved for teens with genotype 1, 4, 5 or 6 chronic HCV infection; Sovaldi was approved in combination with ribavirin, for those with genotype 2 or 3.

The only FDA-approved hep C treatment for children under age 12 is peginterferon plus ribavirin. However, a recent study of children between the ages of 6 and 11 reported excellent HCV cure rates using Harvoni.